Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.
The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 ...
Guggenheim analyst Vamil Divan raised the firm’s price target on Johnson & Johnson to $166 from $162 and keeps a Neutral rating on the ...
New Brunswick, New Jersey-based Johnson & Johnson (JNJ) researches, develops, manufactures, and sells various products in the ...
Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...
Lane Johnson assured he was coming back for the 2025 season, which would be his 13th in the NFL. Johnson is still an All-Pro ...
We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Johnson & Johnson (NYSE: JNJ) didn't have an exceptional 2024; in fact, it was one of the worst-performing stocks on the ...